A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
PHASE3
This is a Phase III Randomized, Controlled, Multicenter, Open-label Study o...
Status
Completed
Location
The First Affiliated Hospital of Anhui Medical University
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
PHASE2
This phase II trial compares the combination of selinexor, daratumumab and ...
Status
Active Not Recruiting
Location
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
PHASE2
The purpose of this study is to assess the efficacy, antitumor activity, sa...
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
PHASE3
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superior...
Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
PHASE3
Allogeneic stem cell (allo SCT) transplantation for multiple myeloma is a p...
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
PHASE3
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer i...
Status
Active Not Recruiting
Location
University of Alabama at Birmingham - Main /ID# 261434